221 related articles for article (PubMed ID: 36928090)
21. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
[No Abstract] [Full Text] [Related]
22. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
Hu H; Cheng R; Wang Y; Wang X; Wu J; Kong Y; Zhan S; Zhou Z; Zhu H; Yu R; Liang G; Wang Q; Zhu X; Zhang CY; Yin R; Yan C; Chen X
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36413402
[TBL] [Abstract][Full Text] [Related]
23. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
24. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I; Roman M; Welch C; Entrialgo-Cadierno R; Salmon M; Santos A; Feliu I; Kovalski J; Lopez I; Rodriguez-Remirez M; Palomino-Echeverria S; Lonfgren SM; Ferrero M; Calabuig S; Ludwig IA; Lara-Astiaso D; Jantus-Lewintre E; Guruceaga E; Narayanan S; Ponz-Sarvise M; Pineda-Lucena A; Lecanda F; Ruggero D; Khatri P; Santamaria E; Fernandez-Irigoyen J; Ferrer I; Paz-Ares L; Drosten M; Barbacid M; Gil-Bazo I; Vicent S
Nat Commun; 2023 Oct; 14(1):6332. PubMed ID: 37816716
[TBL] [Abstract][Full Text] [Related]
25. KRAS: A Druggable Target in Colon Cancer Patients.
Negri F; Bottarelli L; de'Angelis GL; Gnetti L
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456940
[TBL] [Abstract][Full Text] [Related]
26. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
[TBL] [Abstract][Full Text] [Related]
27. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
28. The ERBB network facilitates KRAS-driven lung tumorigenesis.
Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
[TBL] [Abstract][Full Text] [Related]
29. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
30. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
31. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.
Yaeger R; Mezzadra R; Sinopoli J; Bian Y; Marasco M; Kaplun E; Gao Y; Zhao H; Paula ADC; Zhu Y; Perez AC; Chadalavada K; Tse E; Chowdhry S; Bowker S; Chang Q; Qeriqi B; Weigelt B; Nanjangud GJ; Berger MF; Der-Torossian H; Anderes K; Socci ND; Shia J; Riely GJ; Murciano-Goroff YR; Li BT; Christensen JG; Reis-Filho JS; Solit DB; de Stanchina E; Lowe SW; Rosen N; Misale S
Cancer Discov; 2023 Jan; 13(1):41-55. PubMed ID: 36355783
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
[TBL] [Abstract][Full Text] [Related]
33. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
34. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
35. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
36. Strategies for Targeting KRAS: A Challenging Drug Target.
Wadood A; Ajmal A; Rehman AU
Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
[TBL] [Abstract][Full Text] [Related]
37. Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.
Ziv E; Erinjeri JP; Yarmohammadi H; Boas FE; Petre EN; Gao S; Shady W; Sofocleous CT; Jones DR; Rudin CM; Solomon SB
Radiology; 2017 Jan; 282(1):251-258. PubMed ID: 27440441
[TBL] [Abstract][Full Text] [Related]
38. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
Cancer Discov; 2024 Feb; 14(2):308-325. PubMed ID: 37931288
[TBL] [Abstract][Full Text] [Related]
39. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
40. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
